This document is a USPTO patent application (US20260079153A1) filed on November 26, 2025, concerning methods for generating mature neurons from pluripotent stem cells. The core of the invention involves overexpressing the splicing factor muscleblind like splicing regulator 2 (Mbnl2) in cortical neurons, potentially alongside overexpressing RNA binding fox-1 homolog 1 (Rbfox1) and/or reducing polypyrimidine tract binding proteins PTBP1/2. The application aims to facilitate the study of late-onset neurodegenerative diseases, such as tau pathology models, and includes methods for accelerated derivation of mature neurons.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it represents a disclosure of novel methods in the biotechnology and pharmaceutical research space. Companies involved in stem cell research, neurodegenerative disease modeling, or therapeutic development may find this patent application relevant for understanding the state of the art, potential licensing opportunities, or as a basis for their own research and development efforts. No immediate actions are required from a compliance perspective.